ROSTI, GIANANTONIO
ROSTI, GIANANTONIO
G Rosti; Gianantonio Rosti; ROSTI G
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia
2015 Mancini, Manuela; Leo, Elisa; Takemaru, Ken-Ichi; Campi, Virginia; Castagnetti, Fausto; Soverini, Simona; De Benedittis, Caterina; Rosti, Gianantonio; Cavo, Michele; Santucci, Maria Alessandra; Martinelli, Giovanni
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line
2017 Castagnetti, Fausto; Di Raimondo, Francesco; De Vivo, Antonio; Spitaleri, Antonio; Gugliotta, Gabriele; Fabbiano, Francesco; Capodanno, Isabella; Mannina, Donato; Salvucci, Marzia; Antolino, Agostino; Marasca, Roberto; Musso, Maurizio; Crugnola, Monica; Impera, Stefana; Trabacchi, Elena; Musolino, Caterina; Cavazzini, Francesco; Mineo, Giuseppe; Tosi, Patrizia; Tomaselli, Carmela; Rizzo, Michele; Siragusa, Sergio; Fogli, Miriam; Ragionieri, Riccardo; Zironi, Alessandro; Soverini, Simona; Martinelli, Giovanni; Cavo, Michele; Vigneri, Paolo; Stagno, Fabio; Rosti, Gianantonio; Baccarani, Michele
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia
2016 Baccarani, Michele; Gugliotta, Gabriele; Castagnetti, Fausto; Soverini, Simona; Rosti, Gianantonio
A review of the European LeukemiaNet recommendations for the management of CML
2015 Baccarani, Michele; Castagnetti, Fausto; Gugliotta, Gabriele; Rosti, Gianantonio
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia
2005 Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M.
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
2006 Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
2012 S Luatti; F Castagnetti; G Marzocchi; C Baldazzi; G Gugliotta; I Iacobucci; G Specchia; L Zanatta; G Rege-Cambrin; M Mancini; E Abruzzese; A Zaccaria; M G Grimoldi; A Gozzetti; G Ameli; M A Capucci; G Palka; P Bernasconi; F Palandri; F Pane; G Saglio; G Martinelli; G Rosti; M Baccarani; N Testoni; on behalf of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis
2012 Soverini S; Martinelli G.; Rosti G.; Iacobucci I.; Baccarani M.
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival
2014 Massimo Breccia;Luigiana Luciano;Roberto Latagliata;Fausto Castagnetti;Dario Ferrero;Francesco Cavazzini;Malgorzata Monica Trawinska;Mario Annunziata;Fabio Stagno;Mario Tiribelli;Gianni Binotto;Elena Crisà;Pellegrino Musto;Antonella Gozzini;Laura Cavalli;Enrico Montefusco;Alessandra Iurlo;Sabina Russo;Michele Cedrone;Antonella Russo Rossi;Patrizia Pregno;Mauro Endri;Antonio Spadea;Matteo Molica;Gianfranco Giglio;Francesca Celesti;Federica Sorà;Sergio Storti;Ada D’Addosio;Giovanna Rege Cambrin;Alessandro Isidori;Simona Sica;Elisabetta Abruzzese;Giorgina Speccha;Gianantonio Rosti;Giuliana Alimena
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR)
2016 Bernardi Simona, Andrea Di Palma, Federica Cattina, Simone Perucca, Michele Malagola, Mario Tiribelli, Erika Codarin, Maria Teresa Bochicchio, Giuseppina Ruggeri, Luca Franceschini, Valeria Cancelli, Fausto Castagnetti, Simona Soverini, Miriam Fogli, Claudia Venturi, Serena Lavorgna, Chiara Pagani, Cristina Skert, Camilla Zanaglio, Alessandro Turra, Nicola Polverelli, Luigi Caimi, Giuseppe Rossi, Maria Teresa Voso, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani, Domenico Russo
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations
2009 Soverini S; Poerio A; Vitale A; Gnani A; Colarossi S; Castagnetti F.; Iacobucci I; Lonetti A; Palandri F; Rosti G; Amabile M; Paolini S; Papayannidis C; Gugliotta G; Vignetti M; Mandelli F; Baccarani M; Foà R; Martinelli G
Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
2011 Soverini S.; Hochhaus A.; Nicolini F.E.; Gruber F.; Lange T.; Saglio G.; Pane F.; Müller M.C.; Ernst T.; Rosti G.; Porkka K.; Baccarani M.; Cross N.C.; Martinelli G.
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
2014 Zabriskie, M.S.; Eide, C.A.; Tantravahi, S.K.; Vellore, N.A.; Estrada, J.; Nicolini, F.E.; Khoury, H.J.; Larson, R.A.; Konopleva, M.; Cortes, J.E.; Kantarjian, H.; Jabbour, E.J.; Kornblau, S.M.; Lipton, J.H.; Rea, D.; Stenke, L.; Barbany, G.; Lange, T.; Hernandez-Boluda, J.-C.; Ossenkoppele, G.J.; Press, R.D.; Chuah, C.; Goldberg, S.L.; Wetzler, M.; Mahon, F.-X.; Etienne, G.; Baccarani, M.; Soverini, S.; Rosti, G.; Rousselot, P.; Friedman, R.; Deininger, M.; Reynolds, K.R.; Heaton, W.L.; Eiring, A.M.; Pomicter, A.D.; Khorashad, J.S.; Kelley, T.W.; Baron, R.; Druker, B.J.; Deininger, M.W.; O'Hare, T.
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib.
2011 Breccia M.; Latagliata R.; Stagno F.; Luciano L.; Gozzini A.; Castagnetti F.; Fava C.; Cavazzini F.; Annunziata M.; Russo Rossi A.; Pregno P.; Abruzzese E.; Vigneri P.; Rege-Cambrin G.; Sica S.; Pane F.; Santini V.; Specchia G.; Rosti G.; Alimena G.
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia
2017 Mancini, Manuela; Soverini, Simona; Gugliotta, Gabriele; Santucci, MARIA ALESSANDRA; Rosti, Gianantonio; Cavo, Michele; Martinelli, Giovanni; Castagnetti, Fausto
Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50?
2011 Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G.
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.
2010 Zaccaria A; Testoni N; Valenti AM; Luatti S; Tonelli M; Marzocchi G; Cipriani R; Baldazzi C; Giannini B; Stacchini M; Gamberini C; Castagnetti F; Rosti G; Azzena A; Cavazzini F; Cianciulli AM; Dalsass A; Donti E; Giugliano E; Gozzetti A; Grimoldi MG; Ronconi S; Santoro A; Spedicato F; Zanatta L; Baccarani M
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
2008 Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia
Chronic myeloid leukemia. Drug selection in first-line therapy and beyond
2014 Gianantonio, Rosti; Gabriele, Gugliotta; Fausto, Castagnetti
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| 14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia | Mancini, Manuela; Leo, Elisa; Takemaru, Ken-Ichi; Campi, Virginia; Castagnetti, Fausto; Soverini,... Simona; De Benedittis, Caterina; Rosti, Gianantonio; Cavo, Michele; Santucci, Maria Alessandra; Martinelli, Giovanni | 2015-01-01 | PLOS ONE | - | 1.01 Articolo in rivista | Mancini_PONE_2015.pdf; pone.0131074.s001.pdf; pone.0131074.s002.pdf; pone.0131074.s003.pdf; pone.0131074.s004.pdf; pone.0131074.s004.pdf |
| A population-based study of chronic myeloid leukemia patients treated with imatinib in first line | Castagnetti, Fausto; Di Raimondo, Francesco; De Vivo, Antonio; Spitaleri, Antonio; Gugliotta, Gab...riele; Fabbiano, Francesco; Capodanno, Isabella; Mannina, Donato; Salvucci, Marzia; Antolino, Agostino; Marasca, Roberto; Musso, Maurizio; Crugnola, Monica; Impera, Stefana; Trabacchi, Elena; Musolino, Caterina; Cavazzini, Francesco; Mineo, Giuseppe; Tosi, Patrizia; Tomaselli, Carmela; Rizzo, Michele; Siragusa, Sergio; Fogli, Miriam; Ragionieri, Riccardo; Zironi, Alessandro; Soverini, Simona; Martinelli, Giovanni; Cavo, Michele; Vigneri, Paolo; Stagno, Fabio; Rosti, Gianantonio; Baccarani, Michele | 2017-01-01 | AMERICAN JOURNAL OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia | Baccarani, Michele; Gugliotta, Gabriele; Castagnetti, Fausto; Soverini, Simona; Rosti, Gianantonio | 2016-01-01 | - | Springer Verlag | 2.01 Capitolo / saggio in libro | - |
| A review of the European LeukemiaNet recommendations for the management of CML | Baccarani, Michele; Castagnetti, Fausto; Gugliotta, Gabriele; Rosti, Gianantonio | 2015-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia | Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagn...etti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M. | 2005-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. | Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cill...oni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G | 2006-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis | S Luatti; F Castagnetti; G Marzocchi; C Baldazzi; G Gugliotta; I Iacobucci; G Specchia; L Zanatta...; G Rege-Cambrin; M Mancini; E Abruzzese; A Zaccaria; M G Grimoldi; A Gozzetti; G Ameli; M A Capucci; G Palka; P Bernasconi; F Palandri; F Pane; G Saglio; G Martinelli; G Rosti; M Baccarani; N Testoni; on behalf of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML | 2012-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis | Soverini S; Martinelli G.; Rosti G.; Iacobucci I.; Baccarani M. | 2012-01-01 | PHARMACOGENOMICS | - | 1.01 Articolo in rivista | - |
| Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival | Massimo Breccia;Luigiana Luciano;Roberto Latagliata;Fausto Castagnetti;Dario Ferrero;Francesco Ca...vazzini;Malgorzata Monica Trawinska;Mario Annunziata;Fabio Stagno;Mario Tiribelli;Gianni Binotto;Elena Crisà;Pellegrino Musto;Antonella Gozzini;Laura Cavalli;Enrico Montefusco;Alessandra Iurlo;Sabina Russo;Michele Cedrone;Antonella Russo Rossi;Patrizia Pregno;Mauro Endri;Antonio Spadea;Matteo Molica;Gianfranco Giglio;Francesca Celesti;Federica Sorà;Sergio Storti;Ada D’Addosio;Giovanna Rege Cambrin;Alessandro Isidori;Simona Sica;Elisabetta Abruzzese;Giorgina Speccha;Gianantonio Rosti;Giuliana Alimena | 2014-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
| Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) | Bernardi Simona, Andrea Di Palma, Federica Cattina, Simone Perucca, Michele Malagola, Mario Tirib...elli, Erika Codarin, Maria Teresa Bochicchio, Giuseppina Ruggeri, Luca Franceschini, Valeria Cancelli, Fausto Castagnetti, Simona Soverini, Miriam Fogli, Claudia Venturi, Serena Lavorgna, Chiara Pagani, Cristina Skert, Camilla Zanaglio, Alessandro Turra, Nicola Polverelli, Luigi Caimi, Giuseppe Rossi, Maria Teresa Voso, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani, Domenico Russo | 2016-01-01 | BLOOD | - | 1.06 Abstract in rivista | - |
| At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations | Soverini S; Poerio A; Vitale A; Gnani A; Colarossi S; Castagnetti F.; Iacobucci I; Lonetti A; Pal...andri F; Rosti G; Amabile M; Paolini S; Papayannidis C; Gugliotta G; Vignetti M; Mandelli F; Baccarani M; Foà R; Martinelli G | 2009-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. | Soverini S.; Hochhaus A.; Nicolini F.E.; Gruber F.; Lange T.; Saglio G.; Pane F.; Müller M.C.; Er...nst T.; Rosti G.; Porkka K.; Baccarani M.; Cross N.C.; Martinelli G. | 2011-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia | Zabriskie, M.S.; Eide, C.A.; Tantravahi, S.K.; Vellore, N.A.; Estrada, J.; Nicolini, F.E.; Khoury..., H.J.; Larson, R.A.; Konopleva, M.; Cortes, J.E.; Kantarjian, H.; Jabbour, E.J.; Kornblau, S.M.; Lipton, J.H.; Rea, D.; Stenke, L.; Barbany, G.; Lange, T.; Hernandez-Boluda, J.-C.; Ossenkoppele, G.J.; Press, R.D.; Chuah, C.; Goldberg, S.L.; Wetzler, M.; Mahon, F.-X.; Etienne, G.; Baccarani, M.; Soverini, S.; Rosti, G.; Rousselot, P.; Friedman, R.; Deininger, M.; Reynolds, K.R.; Heaton, W.L.; Eiring, A.M.; Pomicter, A.D.; Khorashad, J.S.; Kelley, T.W.; Baron, R.; Druker, B.J.; Deininger, M.W.; O'Hare, T. | 2014-01-01 | CANCER CELL | - | 1.01 Articolo in rivista | - |
| Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies | Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.;... Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G. | 2006-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. | Breccia M.; Latagliata R.; Stagno F.; Luciano L.; Gozzini A.; Castagnetti F.; Fava C.; Cavazzini ...F.; Annunziata M.; Russo Rossi A.; Pregno P.; Abruzzese E.; Vigneri P.; Rege-Cambrin G.; Sica S.; Pane F.; Santini V.; Specchia G.; Rosti G.; Alimena G. | 2011-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia | Mancini, Manuela; Soverini, Simona; Gugliotta, Gabriele; Santucci, MARIA ALESSANDRA; Rosti, Giana...ntonio; Cavo, Michele; Martinelli, Giovanni; Castagnetti, Fausto | 2017-01-01 | ONCOTARGET | - | 1.01 Articolo in rivista | - |
| Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50? | Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G. | 2011-01-01 | THE ONCOLOGIST | - | 1.01 Articolo in rivista | - |
| Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. | Zaccaria A; Testoni N; Valenti AM; Luatti S; Tonelli M; Marzocchi G; Cipriani R; Baldazzi C; Gian...nini B; Stacchini M; Gamberini C; Castagnetti F; Rosti G; Azzena A; Cavazzini F; Cianciulli AM; Dalsass A; Donti E; Giugliano E; Gozzetti A; Grimoldi MG; Ronconi S; Santoro A; Spedicato F; Zanatta L; Baccarani M | 2010-01-01 | CANCER GENETICS AND CYTOGENETICS | - | 1.01 Articolo in rivista | - |
| Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up | Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungo...lino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia | 2008-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Chronic myeloid leukemia. Drug selection in first-line therapy and beyond | Gianantonio, Rosti; Gabriele, Gugliotta; Fausto, Castagnetti | 2014-01-01 | HEMATOLOGY EDUCATION | - | 1.01 Articolo in rivista | - |